J&J Divests OTC Anti-Dandruff Product To Separate Buyers Across 3 Regions
J&J agrees to sell marketing rights to its OTC 1% ketoconazole dandruff treatment product to Kramer Labs in the US and Latin America, to German firm Stada in the EMEA and to UK firm Alliance Pharma for the Asia-Pacific market as it continues to spin off non-core brands and focus on its core $1bn brands.
You may also be interested in...
Consumer Health Sector Holds Private Equity Investors' Attention
"It's amazing with this consumer empowerment how fast that market is growing," biopharma industry veteran Fred Hassan remarks. "Coming up with good products, scientifically validated, supported by doctors and approaching consumers with proper claims, it's a huge opportunity."
FTC ‘Organic’ Guidance Could Help To Curtail Litigation; Comments On 'Green Guides' Update Due 24 April
The US Federal Trade Commission is accepting comments through 24 April on potential updates to its Guides for the Use of Environmental Marketing Claims, aka “Green Guides,” including on whether it should address “organic” product advertising. Angela Diesch, a partner at law firm Amin Talati Wasserman, discusses.
Revlon Sees Light Through Bankruptcy Tunnel, Expects to Emerge In April
New York-based Revlon, Inc. expects to emerge from Chapter 11 bankruptcy after a 3 April meeting with the Bankruptcy Court for the Southern District of New York. The firm says it has settled with a group of unsecured creditors and agreed to financial restructuring that should reduce total debt burden by about $2.7bn.